Anilides

• 

  Subject Areas on Research

  • A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. 
  • A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. 
  • AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. 
  • An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC). 
  • An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. 
  • Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy. 
  • Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. 
  • Biochemical recurrence of prostate cancer. 
  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. 
  • Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. 
  • Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. 
  • Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. 
  • Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. 
  • Cabozantinib in genitourinary malignancies. 
  • Cabozantinib in ovarian clear cell cancers: UnMET expectations. 
  • Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. 
  • Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. 
  • Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. 
  • Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. 
  • Clinical results in cachexia therapeutics. 
  • Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. 
  • Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. 
  • Design of tenofovir-UC781 combination microbicide vaginal gels. 
  • Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. 
  • Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. 
  • Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. 
  • Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. 
  • Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. 
  • Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. 
  • Hedgehog blockade in steroid-refractory sclerotic chronic graft-versus-host disease. 
  • Hedgehog inhibitors with and without adjunctive therapy in treatment of locally advanced basal cell carcinoma. 
  • Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. 
  • Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway. 
  • Isolation, structure and biological activities of platensimycin B4 from Streptomyces platensis. 
  • Ligand-specific dynamics of the androgen receptor at its response element in living cells. 
  • Mammalian chymotrypsin-like enzymes. Comparative reactivities of rat mast cell proteases, human and dog skin chymases, and human cathepsin G with peptide 4-nitroanilide substrates and with peptide chloromethyl ketone and sulfonyl fluoride inhibitors. 
  • Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. 
  • N-Acylated Derivatives of Sulfamethoxazole Block Chlamydia Fatty Acid Synthesis and Interact with FabF. 
  • Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. 
  • Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. 
  • Outcomes of adjunctive therapies post hedgehog inhibitors in the management of locally advanced basal cell carcinoma: A systematic review and pooled analysis. 
  • PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. 
  • Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. 
  • Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. 
  • Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. 
  • Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. 
  • Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. 
  • Platensimycin and platencin congeners from Streptomyces platensis. 
  • Previously unreported adverse reaction to encainide. 
  • Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). 
  • Reduction of granulosa cell progesterone secretion in vitro by intraovarian implants of antiandrogen. 
  • Regulation of the macrophage population in postnatal rat testis. 
  • Reply to B. Rini et al and S. Buti et al. 
  • Shigella flexneri dysentery in the Australian forces in South Vietnam. 
  • Smooth Muscle Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Formation and Rupture of Cerebral Aneurysms in Mice In Vivo. 
  • Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). 
  • THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. 
  • Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. 
  • Treating the biochemical recurrence of prostate cancer after definitive primary therapy. 
  • Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. 
  • Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. 
  • Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. 
  • Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.